Searchable abstracts of presentations at key conferences in endocrinology

ea0037oc9.3 | Adrenal 2 | ECE2015

Modelling the salivary cortisone to serum cortisol inter-relationship to predict serum cortisol under physiological conditions and after hydrocortisone

Debono Miguel , Harrison Robert , Keevil Brian , Whitaker Martin , Digweed Dena , Arlt Wiebke , Ross Richard

Introduction: Measuring serum cortisol to evaluate the normal circadian rhythm and adequacy of hydrocortisone replacement levels requires multiple readings; an expensive, cumbersome process. Conversely, salivary cortisone, a surrogate marker for free cortisol levels is non-invasive and well suited for out-patient settings. We hypothesised that salivary cortisone predicts circulating cortisol levels and can be used as an alternative marker of serum cortisol in a physiological s...

ea0035p30 | Adrenal cortex | ECE2014

Development of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency

Ross Richard , Whitaker Martin , Digweed Dena , Spielmann Sarah , Huatan Hiep , Eckland David , Blankenstein Oliver , Krude Heiko

Background: Current standard treatment for adrenal insufficiency in neonates and infants is unsatisfactory as unlicensed adult dosage formulations are used. These are generally difficult to administer and may give rise to inconsistencies in dose as the content uniformity of the dosage form cannot be verified.Methods: Infacort is a newly-developed immediate release formulation of hydrocortisone that is provided in appropriate unit dosage units (0.5, 1, 2,...

ea0063p664 | Interdisciplinary Endocrinology 1 | ECE2019

Differential regulation of 5β-reductase (AKR1D1) expression and activity by glucocorticoids in human and rodent liver

Nikolaou Nikolaos , Morgan Stuart , Larner Dean , Sharp Anna , Raouf Zachariah , Hughes Beverly , Digweed Dena , Whitaker Martin , Ross Richard , Lavery Gareth , Arlt Wiebke , Gathercole Laura , Tomlinson Jeremy

The prevalence of metabolic syndrome and its hepatic manifestation, non-alcoholic fatty liver disease (NAFLD), continues to escalate. Glucocorticoids (GCs) and bile acids (BAs) are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in human and rodent liver, where it inactivates steroid hormones and catalyses a fundamental step in BA synthesis. We have previously demonstrated that AKR1D1 modulates hepatic GC availability and GC recept...